The role of meta-iodo [131l]benzylguanidine (mibg) in the diagnosis and follow-up of neuroblastoma

A. Miceli, L. Nespoli, G. R. Burgio, C. Aprile, M. Carena, R. Saponaro

Research output: Contribution to journalArticlepeer-review


Fourteen scans employing the adrenergic blocking agent [131I] IJMIBG were performed on JO children with neuroblastoma (NB) or ganglioneuroblastoma (GNB). The scans were negative in 5 cases, and 1 further case produced doubtful results in both the MIBG and CT scan tests. In 4 cases, very positive results were obtained with clear vision of the primary tumor and its metastases. In 1 case, which demonstrated partial differentiation of the outer part of the tumor mass toward GNB, a differentiated tumor specimen did not reveal significant uptake of the tracer. Half-lives of the tracer as measured by external detection in the period 24-48 h after injection were reduced after successful therapy. MIBG scanning appears to be a feasible indicator of NB adrenergic activity, and it can assume a primary role in the staging and follow-up of NB. Higher tumor uptake of the [131I]MIBG and low background offer new perspectives in the radiometabolic treatment of MIBG.

Original languageEnglish
Pages (from-to)37-47
Number of pages11
JournalPediatric Hematology and Oncology
Issue number1
Publication statusPublished - 1986


  • Neuroblastoma
  • Scan

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Cancer Research
  • Management of Technology and Innovation


Dive into the research topics of 'The role of meta-iodo [131l]benzylguanidine (mibg) in the diagnosis and follow-up of neuroblastoma'. Together they form a unique fingerprint.

Cite this